A recent scRNA-seq study found that PRRT3-AS1, an important long non-coding RNA (lncRNA) that has been incorporated in prognostic models for prostate cancer, hepatocellular carcinoma and glioblastoma (GBM), may be required for tumor cell migration in melanoma, suggesting that PRRT3-AS1 is not only a potential prognostic biomarker but also a potential therapeutic target (Zhang et al., 2022; Liang et al., 2018; Fan et al., 2020; Zhang et al., 2021; Y et al., 2021). This evidence concerns the gene PRRT3 and melanoma.